MARINUS PHARMACEUTICALS (MRNS) Covered Calls

You can sell covered calls on MARINUS PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MRNS (prices last updated Wed 4:16 PM ET):

MARINUS PHARMACEUTICALS (MRNS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
7.85 -0.05 7.65 7.88 472K - 0.3B
Covered Calls For MARINUS PHARMACEUTICALS (MRNS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jul 20 7.5 0.35 7.53 -0.4% -48.7%
Aug 17 7.5 1.15 6.73 11.4% 134%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania